Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Parathyroid Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Hyperparathyroidism, Primary 1

Interventions

Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiotherapy 8Doxorubicin 8Nivolumab 7Immunoglobulin G 6Disulfides 6Cisplatin 6Biopsy 6Radiation 5Platinum 5Paclitaxel 5Cytarabine 5Bevacizumab 51,2-diaminocyclohexaneplatinum II citrate 5atezolizumab 4Vincristine 4Taxes 4Prednisone 4Methotrexate 4Daunorubicin 4Cyclophosphamide 4Cetuximab 4Carboplatin 4prednylidene 3merphos 3liposomal doxorubicin 3deltacortene 3Temozolomide 3Radiotherapy, Intensity-Modulated 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NIH × fluorocholine × Clear all
NCT07444723 2026-06-02

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

National Institutes of Health Clinical Center (CC)

Phase 2/3 Recruiting
193 enrolled
EndocrineHead & Neck

Parathyroid Neoplasms, Multiple Endocrine Neoplasia Type 1, Hyperparathyroidism, Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡